Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma

Publication date: Mar 16, 2019

At a minimum follow-up of 12 months, incidence of treatment-related grade 3 to 5 AEs was 34% with NIVO3+IPI1 versus 48% with NIVO1+IPI3 (P=. 006).

In descriptive analyses, objective response rate was 45. 6% in the NIVO3+IPI1 group and 50. 6% in the NIVO1+IPI3 group, with complete responses in 15. 0% and 13. 5% of patients, respectively.

The CheckMate 511 study met its primary end point, demonstrating a significantly lower incidence of treatment-related grade 3-5 AEs with NIVO3+IPI1 versus NIVO1+IPI3.

Concepts Keywords
Incidence Melanoma
Ipilimumab Nivolumab
Median Ipilimumab
Melanoma Drugs
Toxicity Clinical medicine
Bristol-Myers Squibb
III melanoma
Melanoma

Semantics

Type Source Name
drug DRUGBANK Nivolumab
drug DRUGBANK Ipilimumab
disease MESH Melanoma
disease DOID Melanoma
pathway BSID Melanoma
drug DRUGBANK Nonoxynol-9
gene UNIPROT WDR18
gene UNIPROT TEX10
disease MESH disease progression
gene UNIPROT AES
drug DRUGBANK Methionine
gene UNIPROT SLTM
gene UNIPROT MET
gene UNIPROT RNMT
drug DRUGBANK Tropicamide

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *